Pulmonx (LUNG) Free Cash Flow (2019 - 2025)

Pulmonx (LUNG) has reported Free Cash Flow for 7 consecutive years, with -$8.2 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Free Cash Flow fell 8.23% year-over-year to -$8.2 million in Q3 2025; TTM through Sep 2025 was -$32.6 million, a 6.25% increase from a year earlier, with the FY2024 full-year figure at -$33.0 million, up 14.14% from the prior year.
• Free Cash Flow was -$8.2 million for Q3 2025 at Pulmonx, down from -$3.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$3.9 million in Q2 2025 and troughed at -$15.6 million in Q1 2022.
• A 5-year average of -$9.9 million and a median of -$9.9 million in 2021 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow slumped 72.67% in 2021 and jumped 37.82% in 2025, its largest moves.
• Over 5 years, Free Cash Flow stood at -$11.8 million in 2021, then gained by 15.8% to -$10.0 million in 2022, then advanced by 13.69% to -$8.6 million in 2023, then increased by 20.55% to -$6.8 million in 2024, then retreated by 20.6% to -$8.2 million in 2025.
• The last three Free Cash Flow figures came in at -$8.2 million (Q3 2025), -$3.9 million (Q2 2025), and -$13.6 million (Q1 2025), per Business Quant data.